The effect of intracameral bevacizumab on current hyphema
The effect of intracameral bevacizumab on current hyphema
Aim: The aim of this study was to investigate the effect of intracameral bevacizumab on the current hyphema.Material and Methods: The animals were assigned to the following 4 groups; Group 1: One 2.5 mg bevacizumab injection to theanterior chamber; Group 2: One 1.25 mg bevacizumab injection to the anterior chamber; Group 3: One 1cc balanced salt solutioninjection to the anterior chamber; and Group 4: Untreated hyphema group. Non-heparinized blood that obtained from the rabbit earwas used to fill the anterior chamber to create total hyphema. Intraocular pressures (IOP), hyphema resorption time, clot formation,peripheral synechia formation, and corneal staining were recorded.Results: IOP results were 26±1.2, 30±2.1, 24±2.9, and 22±0.0 mm Hg for groups 1, 2, 3, and 4, respectively, and were significantlyhigher in group 2 than in the other groups (p= 0.001). Resorption times of hyphema were 13±2.2, 13±3.2, 9±1.7, and 9±1.6 days forgroups 1, 2, 3, and 4, respectively, and were significantly longer for the groups receiving bevacizumab than for the others (p=0.018).The clot formation scores were 0.16±0.41, 0.14±0.38, 0.86±0.38, and 1.0±0.0 for groups 1, 2, 3, and 4, respectively, and weresignificantly lower for the groups receiving bevacizumab than in the other groups (p= 0.002). The peripheral synechia formationscores were 0.0±0.0, 0.0±0.0, 0.43±0.53, and 0.50±0.54 for groups 1, 2, 3, and 4, respectively, and were not significantly different (p=0.213). The corneal staining scores were 0.85±0.35, 0.86±0.38, 0.14±0.38, and 0.14±0.38 for groups 1, 2, 3, and 4, respectively, andwere significantly higher for the groups receiving bevacizumab (p= 0.035).Conclusion: Intracameral bevacizumab may increase complications that related current hyphema.
___
- 1. Bansal S, Gunasekeran DV, Ang B, et al. Controversies in
the pathophysiology and management of hyphema. Surv
Ophthalmol 2016;61:297-308.
- 2. Walton W, Von Hagen S, Grigorian R, et al. Management of
traumatic hyphema. Surv Ophthalmol 2002;47:297-334.
- 3. Bausback HJ. Clinical management of hyphema. Clin Eye
Vis Care 1995;7:83-90.
- 4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab
plus irinotecan, fluorouracil, and leucovorin for metastatic
colorectal cancer. N Engl J Med 2004;350:2335-42.
- 5. Adamis AP, Shima DT. The role of vascular endothelial growth
factor in ocular health and disease. Retina 2005;25:111-8.
- 6. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement
following intravitreal bevacizumab (Avastin) in exudative
age related macular degeneration. Retina 2006;26:994-98.
- 7. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term
safety and efficacy of intravitreal bevacizumab (Avastin)
for neovascular age-related macular degeneration. Retina
2006;26:495-511.
- 8. Grisanti S, Biester S, Peters S, et al. Intracameral
bevacizumab for iris rubeosis. Am J Ophthalmol
2006;142:158-60.
- 9. Bhagat PR, Agrawal KU, Tandel D. Study of the Effect
of Injection Bevacizumab through Various Routes in
Neovascular Glaucoma. J Curr Glaucoma Pract 2016;10:39-
48.
- 10. Colak C, Parlakpınar H. [Animals in research: reporting In
vivo experiments: ARRIVE guidelines-review]. J Turgut Ozal
Med Cent 2012;19:128-31.
- 11. Zhou M, Xu X, Zhang X, et al. Clinical outcomes of Ahmed
Glaucoma valve implantation with or without intravitreal
bevacizumab pretreatment for neovascular glaucoma:
a systematic review and meta-analysis. J Glaucoma.
2016;25:551-7.
- 12. Zhang H, Huang Z, Zou X, et al. Bevacizumab and woundhealing
complications: a systematic review and metaanalysis
of randomized controlled trials. Oncotarget
2016;7:82473-81.
- 13. Karcioglu ZA, Mullaney PB. Diagnosis and management
of iris juvenile xanthogranuloma. J Paediatr Ophthalmol
Strabismus 1997;34:44-51.
- 14. Reggi JR, Hida RY, Hida MM, et al. Subconjunctival and
topical application of recombinant tissue plasminogen
activator in rabbits. Arq Bras Oftalmol 2015;78:6-9.
- 15. Saxena R, Koudstaal P. Anticoagulant versus antiplatelet
therapy for preventing stroke in patients with nonrheumatic
atrial fibrillation and a history of stroke or transient ischemic
attack. Cochrane Database Syst Rev 2004;18:CD000187.
- 16. Gharaibeh A, Savage HI, Scherer RW, et al. Medical
interventions for traumatic hyphema. Cochrane Database
Syst Rev 2019;1:CD005431.
- 17. Sohn HJ, Han DH, Lee DY, et al. Changes in aqueous cytokines
after intravitreal triamcinolone versus bevacizumab for
macular oedema in branch retinal vein occlusion. Acta
Ophthalmol 2014;92:217-24.
- 18. Brodrick JD. Corneal blood staining after hyphaema. Br J
Ophthalmol 1972; 56:589-93.
- 19. Crouch ER, Williams PB. Trauma: ruptures and bleeding.
In: Tasmani W, Jager EM, editors. Duane’s Clinical
Ophthalmology. Philadelphia: Lippincott; 1993. p. 1-18.
- 20. Gottsch JD, Messner EP, McNair DS, et al. Corneal blood
staining: an animal model. Ophthalmology 1986;93:97-802.
- 21. Read J. Traumatic hyphema: surgical vs medical
management. Ann Ophthalmol 1975;7:659-62.
- 22. Yang X, Zhou Q, Du S. Conjunctival flap covering in the
treatment of corneal blood staining. Can J Ophthalmol
2011;46:442-43.
- 23. Duch S, Buchacra O, Milla E, et al. Intracameral bevacizumab
(Avastin) for neovascular glaucoma: a pilot study in 6
patients. J Glaucoma 2009;18:140-3.
- 24. Park HY, Kim SJ, Lee HB, et al. Effect of intracameral
bevacizumab injection on corneal endothelium in rabbits.
Cornea 2008;27:1151-5.
- 25. Chiang CC, Chen WL, Lin JM, et al. Effect of bevacizumab
on human corneal endothelial cells: a six-month follow-up
study. Am J Ophthalmol 2008;146:688-91.
- 26. Fernández Jiménez-Ortiz H, Perucho Martinez S, Toledano
Fernández N, et al. Intracameral bevacizumab (Avastin®)
in the management of neovascular glaucoma surgery. Arch
Soc Esp Oftalmol 2012;87:396-400.
- 27. Olmos LC, Lee RK. Medical and surgical treatment of
neovascular glaucoma. Int Ophthalmol Clin 2011;51:27-36.
- 28. Ghanem AA, El-Kannishy AM, El-Wehidy AS, et al. Intravitreal
bevacizumab (avastin) as an adjuvant treatment in cases
of neovascular glaucoma. Middle East Afr J Ophthalmol
2009;16:75-9.
- 29. Wolf A, von Jagow B, Ulbig M, et al. Intracameral injection
of bevacizumab for the treatment of neovascular glaucoma.
Ophthalmologica 2011;226: 51-6.